Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new In Vitro pharmacokinetic/pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 403-410

  Meletiadis, Joseph ^a   Al Saigh, Rafal ^a   Velegraki, Aristea ^b   Walsh, Thomas J ^c   Roilides, Emmanuel ^d   Zerva, Loukia ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; GALACTOMANNAN; VORICONAZOLE;

ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BIOASSAY; DRUG CLEARANCE; DRUG INHIBITION; FUNGUS GROWTH; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERISTALTIC PUMP; PHARMACODYNAMICS; PLASMA; PRIORITY JOURNAL; SIMULATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; DIFFUSION CHAMBERS, CULTURE; ECHINOCANDINS; HUMANS; MANNANS; MICROBIAL SENSITIVITY TESTS; PULSATILE FLOW; PYRIMIDINES; SPECIES SPECIFICITY; SPORES, FUNGAL; TRIAZOLES;

EID: 84455169873     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00662-11     Document Type: Article

References (37)

1. Andes D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. 20:679-697. (Pubitemid 44375115)
2. Ayestarán A, et al. 1996. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob. Agents Chemother. 40:609-612. (Pubitemid 26075429)
3. Bekersky I, et al. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833. (Pubitemid 34157670)
4. Cantón E, Espinel-Ingroff A, Peman J. 2009. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev. Anti Infect. Ther. 7:107-119.
5. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. Second edition. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Denning DW, et al. 1998. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J. Infect. 37:173-180. (Pubitemid 28482922)
7. Espinel-Ingroff A, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
8. Fedorova ND, et al. 2008. Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus. PLoS Genet. 4:e1000046.
9. Groll AH, Piscitelli SC, Walsh TJ. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44:343-500.
10. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
11. Herbrecht R, et al. 2010. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 45:1227-1233.
12. Johnson EM, et al. 2000. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45:85-93. (Pubitemid 30060238)
13. Lewis RE, Kontoyiannis DP, Darouiche RO, Raad II, Prince RA. 2002. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob. Agents Chemother. 46:3499-3505. (Pubitemid 35192917)
14. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. 1998. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42: 1382-1386. (Pubitemid 28257636)
15. Lewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP. 2006. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J. Antimicrob. Chemother. 57:288-293. (Pubitemid 43160171)
16. Li RC, Zhu ZY. 1997. In vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective. J. Chemother. 9(Suppl. 1):55-63. (Pubitemid 27294755)
17. Lignell A, Johansson A, Lowdin E, Cars O, Sjolin J. 2007. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole. Clin. Microbiol. Infect. 13:613- 619.
18. Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. 2005. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy 25: 1174-1180. (Pubitemid 41242577)
19. Marr KA, Patterson T, Denning D. 2002. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North Am. 16: 875-894. (Pubitemid 35477517)
20. Meletiadis J, et al. 2007. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob. Agents Chemother. 51:3329 -3337.
21. Mosquera J, et al. 2001. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob. Agents Chemother. 45:1456 -1462.
22. Murphy M, Bernard EM, Ishimaru T, Armstrong D. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698. (Pubitemid 27098427)
23. Odds FC, et al. 1998. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42:282-288. (Pubitemid 28114432)
24. Patterson TF, et al. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79:250-260. (Pubitemid 30616973)
25. Perea S, et al. 2000. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob. Agents Chemother. 44:1209-1213. (Pubitemid 30228296)
26. Petraitiene R, et al. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23. (Pubitemid 34031596)
27. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2010. Wild-type MIC distributions, epidemiological cutoff values and speciesspecific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
28. Purkins L, et al. 2003. The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56(Suppl. 1):2-9. (Pubitemid 37491727)
29. Rodríguez-Tudela JL, Arendrup MC, Cuenca-Estrella M, Donnelly JP, Lass-Florl C. 2010. EUCAST breakpoints for antifungals. Drug News Perspect. 23:93-97.
30. Shadomy S, McCay JA, Schwartz SI. 1969. Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl. Microbiol. 17:497-503.
31. Steinbach WJ, et al. 2004. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis. 39:192-198. (Pubitemid 38971489)
32. Takemoto K, et al. 2009. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Chemotherapy 55:105-113.
33. Tekaia F, Latge JP. 2005. Aspergillus fumigatus: saprophyte or pathogen? Curr. Opin. Microbiol. 8:385-392. (Pubitemid 41021897)
34. Walsh TJ, et al. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49: 4536-4545. (Pubitemid 41552583)
35. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 327-360. (Pubitemid 351265310)
36. Walsh TJ, et al. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319. (Pubitemid 36898165)
37. Warn PA, et al. 2006. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother. 58: 1198-1207. (Pubitemid 44884139)